BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

797 related articles for article (PubMed ID: 35741714)

  • 1. Construction and Validation of a Tumor Microenvironment-Based Scoring System to Evaluate Prognosis and Response to Immune Checkpoint Inhibitor Therapy in Lung Adenocarcinoma Patients.
    Huang P; Xu L; Jin M; Li L; Ke Y; Zhang M; Zhang K; Lu K; Huang G
    Genes (Basel); 2022 May; 13(6):. PubMed ID: 35741714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
    Zeng W; Wang J; Yang J; Chen Z; Cui Y; Li Q; Luo G; Ding H; Ju S; Li B; Chen J; Xie Y; Tong X; Liu M; Zhao J
    Front Immunol; 2023; 14():1217590. PubMed ID: 37492563
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
    Fan T; Pan S; Yang S; Hao B; Zhang L; Li D; Geng Q
    Front Immunol; 2021; 12():693062. PubMed ID: 34497605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pan-Cancer Analysis of Immune Cell Infiltration Identifies a Prognostic Immune-Cell Characteristic Score (ICCS) in Lung Adenocarcinoma.
    Zuo S; Wei M; Wang S; Dong J; Wei J
    Front Immunol; 2020; 11():1218. PubMed ID: 32714316
    [No Abstract]   [Full Text] [Related]  

  • 5. Comprehensive molecular analyses of cuproptosis-related genes with regard to prognosis, immune landscape, and response to immune checkpoint blockers in lung adenocarcinoma.
    Li R; Tong R; Zhang JL; Zhang Z; Deng M; Hou G
    J Cancer Res Clin Oncol; 2024 May; 150(5):246. PubMed ID: 38722401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
    Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
    Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A risk model developed based on tumor microenvironment predicts overall survival and associates with tumor immunity of patients with lung adenocarcinoma.
    Wu J; Li L; Zhang H; Zhao Y; Zhang H; Wu S; Xu B
    Oncogene; 2021 Jul; 40(26):4413-4424. PubMed ID: 34108619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An ICD-Associated DAMP Gene signature predicts survival and immunotherapy response of patients with lung adenocarcinoma.
    Wu Y; Li K; Liang S; Lou X; Li Y; Xu D; Wu Y; Wang Y; Cui W
    Respir Res; 2023 May; 24(1):142. PubMed ID: 37259066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune signature-based risk stratification and prediction of immune checkpoint inhibitor's efficacy for lung adenocarcinoma.
    Yi M; Li A; Zhou L; Chu Q; Luo S; Wu K
    Cancer Immunol Immunother; 2021 Jun; 70(6):1705-1719. PubMed ID: 33386920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognosis and immunotherapy significances of a cancer-associated fibroblasts-related gene signature in lung adenocarcinoma.
    Luo Y; Zhang S; Xie H; Su Q; He S; Lei Z
    Cell Mol Biol (Noisy-le-grand); 2023 Dec; 69(14):51-61. PubMed ID: 38279482
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Construction and validation of a prognostic model for lung adenocarcinoma based on endoplasmic reticulum stress-related genes.
    Li F; Niu Y; Zhao W; Yan C; Qi Y
    Sci Rep; 2022 Nov; 12(1):19857. PubMed ID: 36400857
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of radiotherapy-related autophagy genes in the prognosis and immune infiltration in lung adenocarcinoma.
    Gao J; Lu F; Yan J; Wang R; Xia Y; Wang L; Li L; Chang L; Li W
    Front Immunol; 2022; 13():992626. PubMed ID: 36311724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High Expression of DLGAP5 Indicates Poor Prognosis and Immunotherapy in Lung Adenocarcinoma and Promotes Proliferation through Regulation of the Cell Cycle.
    Tang X; Zhou H; Liu Y
    Dis Markers; 2023; 2023():9292536. PubMed ID: 36712920
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of a TGF-β signaling-related gene signature for prediction of immunotherapy and targeted therapy for lung adenocarcinoma.
    Yu Q; Zhao L; Yan XX; Li Y; Chen XY; Hu XH; Bu Q; Lv XP
    World J Surg Oncol; 2022 Jun; 20(1):183. PubMed ID: 35668494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Integration of multiple key molecules in lung adenocarcinoma identifies prognostic and immunotherapeutic relevant gene signatures.
    Wu Q; Wang L; Wei H; Li B; Yang J; Wang Z; Xu J; Zhou YL; Zhang B
    Int Immunopharmacol; 2020 Jun; 83():106477. PubMed ID: 32278127
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma.
    Yang L; He YT; Dong S; Wei XW; Chen ZH; Zhang B; Chen WD; Yang XR; Wang F; Shang XM; Zhong WZ; Wu YL; Zhou Q
    J Immunother Cancer; 2022 Jan; 10(2):. PubMed ID: 35140113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. NGEF is a potential prognostic biomarker and could serve as an indicator for immunotherapy and chemotherapy in lung adenocarcinoma.
    Chen X; Zhang T; He YQ; Miao TW; Yin J; Ding Q; Yang M; Chen FY; Zeng HP; Liu J; Zhu Q
    BMC Pulm Med; 2024 May; 24(1):248. PubMed ID: 38764064
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and validation of polyamines metabolism-associated gene signatures to predict prognosis and immunotherapy response in lung adenocarcinoma.
    Wang N; Chai M; Zhu L; Liu J; Yu C; Huang X
    Front Immunol; 2023; 14():1070953. PubMed ID: 37334367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic and immunogenomic analysis of three prognostic signature genes in LUAD.
    Feng HM; Zhao Y; Yan WJ; Li B
    BMC Bioinformatics; 2023 Jan; 24(1):19. PubMed ID: 36650426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification and validation of tumor environment phenotypes in lung adenocarcinoma by integrative genome-scale analysis.
    Bi G; Chen Z; Yang X; Liang J; Hu Z; Bian Y; Sui Q; Li R; Zhan C; Fan H
    Cancer Immunol Immunother; 2020 Jul; 69(7):1293-1305. PubMed ID: 32189030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 40.